Reuters- The University of Oxford has said that it had paused a small United Kingdom trial testing the Covid-19 vaccine it developed with AstraZeneca Plc in children and teenagers.
The University said this yesterday explaining that it waits for more data on rare blood clotting issues in adults who received the shot.
The trial disruption is the latest blow to the vaccine, once hailed as a milestone in the fight against the pandemic, after several countries restricted its use in light of reports of medical issues after inoculations.
There were no safety concerns in the paediatric trial, Oxford University said, adding that it would await guidance from the UK drugs watchdog before giving any further vaccinations.
The university said in February it planned to enrol 300 volunteers aged 6-17 years, based in the United Kingdom, as part of this study.
The European Medicines Agency (EMA) is currently reviewing reports of an extremely rare brain blood clot known as cerebral venous sinus thrombosis (CVST) after the AstraZeneca shots, and is expected to announce its findings on Wednesday or Thursday.
A senior EMA official has said there is a clear association between the vaccine and CVST, though the direct cause of the clots is still unknown.
IMF sees stronger global growth as some Covid clouds begin to clear
Canada’s hospitals deploy artificial lungs, scramble for staff as Covid-19 hits younger patients
Global COVID-19 death toll surpasses 3 million amid new infections resurgence
The World Health Organization, which is closely studying the latest data on AstraZeneca’s vaccine alongside other regulators, said on Tuesday it expects to there will be no reason to change its assessment that the shot’s benefits outweigh any risks.
Spats with governments across Europe about production, supplies, possible side effects and the vaccine’s merits have dogged the Anglo-Swedish drug maker for months.
Anthony Fauci, the top U.S. infectious disease doctor, told Reuters last week the United States may not need AstraZeneca’s vaccine, even if it wins regulatory approval.